Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Athira Pharma Inc (NQ: ATHA ) 0.4281 -0.0219 (-4.87%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 6,054,422 Open 0.4500 Bid (Size) 0.5310 (35) Ask (Size) 0.5400 (13) Prev. Close 0.4500 Today's Range 0.4200 - 0.4500 52wk Range 0.4115 - 4.298 Shares Outstanding 38,054,583 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 12 Health Care Stocks Moving In Thursday's After-Market Session Today 16:34 EDT Via Benzinga Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting October 22, 2024 From Athira Pharma, Inc. Via GlobeNewswire Performance YTD -85.19% -85.19% 1 Month -4.01% -4.01% 3 Month -86.58% -86.58% 6 Month -79.01% -79.01% 1 Year -72.56% -72.56% More News Read More Robinhood To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Thursday September 19, 2024 Via Benzinga Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases September 17, 2024 From Athira Pharma, Inc. Via GlobeNewswire Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings September 04, 2024 Via Benzinga Exposures Fossil Fuels US Stocks Mixed; Trade Gap Widens In July September 04, 2024 Via Benzinga Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks September 04, 2024 Via Benzinga Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket September 04, 2024 Via Benzinga Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease September 03, 2024 From Athira Pharma, Inc. Via GlobeNewswire ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024 August 01, 2024 Via InvestorPlace Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates August 01, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024 July 31, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease July 09, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients June 12, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS) June 11, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma to Participate in Upcoming June Conferences May 29, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action May 17, 2024 From Athira Pharma, Inc. Via GlobeNewswire ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024 May 15, 2024 Via InvestorPlace Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates May 15, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma to Participate in Upcoming May Conferences May 02, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer April 15, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease April 11, 2024 From Athira Pharma, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session March 27, 2024 Via Benzinga Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference March 08, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting April 03, 2024 From Athira Pharma, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.